Effect of high-dose ifosfamide in advanced soft tissue sarcomas. A multicentre phase II study of the EORTC Soft Tissue and Bone Sarcoma Group.

2.50
Hdl Handle:
http://hdl.handle.net/10541/86537
Title:
Effect of high-dose ifosfamide in advanced soft tissue sarcomas. A multicentre phase II study of the EORTC Soft Tissue and Bone Sarcoma Group.
Authors:
Nielsen, O S; Judson, I; Van Hoesel, Q; Le Cesne, A; Keizer, H J; Blay, Jean-Yves; Van Oosterom, A; Radford, John A ( 0000-0001-7898-2786 ) ; Svancárová, L; Krzemienlecki, K; Hermans, C; Van Glabbeke, Martine M; Oosterhuis, J W; Verweij, J
Abstract:
In this phase II study the effect of high-dose ifosfamide (HDI) given as a 3-day continuous infusion at a dose of 12 g/m2 repeated every 4 weeks with adequate mesna protection and hydration was evaluated in patients with advanced soft tissue sarcomas. A total of 124 patients entered the trial of which 10 were ineligible. HDI was given both as first-line and second-line chemotherapy. Median age was 46 years (19-66 years). Median World Health Organization (WHO) performance status was 1 (0-1). Fifty two per cent of the patients were males. The predominant histology was leiomyosarcoma (33%). A maximum of six cycles was given. At the time of analysis 55 patients have died. The partial response (PR) rate was 16%. The median time to progression was 15 weeks. 8 of the 18 responding patients (44%) had synovial sarcomas, whereas only 5% of the patients having leiomyosarcomas responded. The grade 3 + 4 haematological toxicity encountered was neutrophils in 78% and platelets in 12%. The major grade 3 + 4 non-haematological toxicities encountered were febrile neutropenia in 39%, infection in 20%, and acute renal failure in 4%. In conclusion, it is possible to administer HDI on a multicentre basis, but the toxicity is substantial. HDI given as a continuous infusion at this dose cannot be recommended as the standard treatment of advanced soft tissue sarcomas, even in selected patients.
Affiliation:
Centre for Bone and Soft Tissue Sarcomas, Aarhus University Hospital, Denmark. osn@onko.aau.dk
Citation:
Effect of high-dose ifosfamide in advanced soft tissue sarcomas. A multicentre phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. 2000, 36 (1):61-7 Eur. J. Cancer
Journal:
European Journal of Cancer
Issue Date:
Jan-2000
URI:
http://hdl.handle.net/10541/86537
DOI:
10.1016/S0959-8049(99)00240-3
PubMed ID:
10741296
Type:
Article
Language:
en
ISSN:
0959-8049
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorNielsen, O Sen
dc.contributor.authorJudson, Ien
dc.contributor.authorVan Hoesel, Qen
dc.contributor.authorLe Cesne, Aen
dc.contributor.authorKeizer, H Jen
dc.contributor.authorBlay, Jean-Yvesen
dc.contributor.authorVan Oosterom, Aen
dc.contributor.authorRadford, John Aen
dc.contributor.authorSvancárová, Len
dc.contributor.authorKrzemienlecki, Ken
dc.contributor.authorHermans, Cen
dc.contributor.authorVan Glabbeke, Martine Men
dc.contributor.authorOosterhuis, J Wen
dc.contributor.authorVerweij, Jen
dc.date.accessioned2009-11-19T17:14:19Z-
dc.date.available2009-11-19T17:14:19Z-
dc.date.issued2000-01-
dc.identifier.citationEffect of high-dose ifosfamide in advanced soft tissue sarcomas. A multicentre phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. 2000, 36 (1):61-7 Eur. J. Canceren
dc.identifier.issn0959-8049-
dc.identifier.pmid10741296-
dc.identifier.doi10.1016/S0959-8049(99)00240-3-
dc.identifier.urihttp://hdl.handle.net/10541/86537-
dc.description.abstractIn this phase II study the effect of high-dose ifosfamide (HDI) given as a 3-day continuous infusion at a dose of 12 g/m2 repeated every 4 weeks with adequate mesna protection and hydration was evaluated in patients with advanced soft tissue sarcomas. A total of 124 patients entered the trial of which 10 were ineligible. HDI was given both as first-line and second-line chemotherapy. Median age was 46 years (19-66 years). Median World Health Organization (WHO) performance status was 1 (0-1). Fifty two per cent of the patients were males. The predominant histology was leiomyosarcoma (33%). A maximum of six cycles was given. At the time of analysis 55 patients have died. The partial response (PR) rate was 16%. The median time to progression was 15 weeks. 8 of the 18 responding patients (44%) had synovial sarcomas, whereas only 5% of the patients having leiomyosarcomas responded. The grade 3 + 4 haematological toxicity encountered was neutrophils in 78% and platelets in 12%. The major grade 3 + 4 non-haematological toxicities encountered were febrile neutropenia in 39%, infection in 20%, and acute renal failure in 4%. In conclusion, it is possible to administer HDI on a multicentre basis, but the toxicity is substantial. HDI given as a continuous infusion at this dose cannot be recommended as the standard treatment of advanced soft tissue sarcomas, even in selected patients.en
dc.language.isoenen
dc.subject.meshAdult-
dc.subject.meshAged-
dc.subject.meshAged, 80 and over-
dc.subject.meshAntineoplastic Agents, Alkylating-
dc.subject.meshFemale-
dc.subject.meshFollow-Up Studies-
dc.subject.meshHumans-
dc.subject.meshIfosfamide-
dc.subject.meshMale-
dc.subject.meshMiddle Aged-
dc.subject.meshPatient Compliance-
dc.subject.meshSarcoma-
dc.subject.meshSurvival Analysis-
dc.titleEffect of high-dose ifosfamide in advanced soft tissue sarcomas. A multicentre phase II study of the EORTC Soft Tissue and Bone Sarcoma Group.en
dc.typeArticleen
dc.contributor.departmentCentre for Bone and Soft Tissue Sarcomas, Aarhus University Hospital, Denmark. osn@onko.aau.dken
dc.identifier.journalEuropean Journal of Canceren

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.